Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jerusalem Pharmaceutical CoXPAE:JPH 82 Dividend Yield % is 4.20% as of Jul. 28, 2026, which is 39% above its 10-year median of 3.03. GuruFocus rates XPAE:JPH with a GF Score™ of 82/100 and a GF Value™ of $2.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 514 Drug Manufacturers companies, Jerusalem Pharmaceutical Co ranks better than 82.88% on this metric.
During the past 12 months, Jerusalem Pharmaceutical Co's average Dividends Per Share Growth Rate was -20.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -12.60% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Jerusalem Pharmaceutical Co was 7.70% per year. The lowest was -12.60% per year. And the median was -2.45% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Jerusalem Pharmaceutical Co (XPAE:JPH) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co Dividend Yield % Chart
XPAE:JPH vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jerusalem Pharmaceutical Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jerusalem Pharmaceutical Co Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jerusalem Pharmaceutical Co's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Jerusalem Pharmaceutical Co's Dividend Yield % falls into.
Jerusalem Pharmaceutical Co Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Jerusalem Pharmaceutical Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.150000
2026-04-16
2026-04-19
2026-05-20
Cash Dividend
annually
USD:USD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co (XPAE:JPH) has a Dividend Yield % of 4.20% as of Jul. 28, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Jerusalem Pharmaceutical Co and its competitors. This is 39% above median its historical median of 3.03. Over the past decade, Jerusalem Pharmaceutical Co's Dividend Yield % has ranged from 1.03 to 5.10. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #88 out of 514 companies in the Drug Manufacturers industry, placing it in the top 17.1%.
Is Jerusalem Pharmaceutical Co's Dividend Yield % too high?
Jerusalem Pharmaceutical Co's current Dividend Yield % of 4.20% is 39% above median its 10-year median of 3.03. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 5.10. The Drug Manufacturers industry median Dividend Yield % is 1.96. Jerusalem Pharmaceutical Co's value of 4.20% is 114.3% above this industry median. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #88 out of 514 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #88 out of 514 companies for Dividend Yield %. This places Jerusalem Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.96. Jerusalem Pharmaceutical Co's value of 4.20% is 114.3% above this benchmark. Historically, Jerusalem Pharmaceutical Co's own Dividend Yield % has ranged from 1.03 to 5.10 over the past decade. While the company's 10-year median is 3.03 vs. the industry median of 1.96, Jerusalem Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.96, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jerusalem Pharmaceutical Co's current Dividend Yield % of 4.20% is 114.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Jerusalem Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jerusalem Pharmaceutical Co's current Dividend Yield % is 4.20%, which is 39% above median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $3.57 — trading 48.1% above its estimated fair value. The current Dividend Yield % is 4.20%, which is 39% above median its 10-year median of 3.03 and 114.3% above the Drug Manufacturers industry median of 1.96. Jerusalem Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current Dividend Yield % is 4.20% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.57 is trading 48.1% above its estimated GF Value™ of $2.41.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
Dividend Yield %: 4.20% (39% above median its 10-year median of 3.03)
GF Value™: $2.41 vs. price of $3.57 (48.1% above fair value)
Industry Position: 114.3% above the Drug Manufacturers median (#88 of 514)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
82GF Score
Get the complete analysis for XPAE:JPH
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
